Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glafenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glafenine SCHEMBL24246 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL29438081 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL18309846 | 0.90 | CYP3A4 (0.84) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL18292475 | 0.89 | CYP1A2 (0.81) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL6026546 | 0.88 | HSD17B10 (0.80) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Floctafenine SCHEMBL28086336 | 0.88 | CYP3A4 (0.79) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL11462321 | 0.87 | CYP1A2 (0.78) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL8207540 | 0.84 | PTGS1 (0.72) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL21346888 | 0.84 | KDM4E (0.73) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL4730108 | 0.84 | CYP1A2 (0.73) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009351-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therepeutics Inc. | 2011-01-13 | — | — | US | claimed |
| EP-2152276-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therapeutics Inc. (CA) | 2010-02-17 | — | — | EP | claimed |
| WO-2008138123-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | THOMAS DAVID Y (CA) | 2008-11-20 | — | — | WO | claimed |
| EP-0068954-B1 | PHARMACEUTICAL COMPOSITION WITH ANTALGIC ACTIVITY | PIERRE FABRE S.A. (FR) | 1984-09-26 | — | — | EP | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-9393221-B2 | Methods and compounds for reducing intracellular lipid storage | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20130023488-A1 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | US | disclosed |
| US-20110009351-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therepeutics Inc. | 2011-01-13 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2152276-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therapeutics Inc. (CA) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008138123-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | THOMAS DAVID Y (CA) | 2008-11-20 | — | — | WO | disclosed |
| EP-0068954-A1 | Pharmaceutical composition with antalgic activity | PIERRE FABRE S.A. (FR) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | PTGS1 204/4885PTGS2 239/4885CYP1A2 2305/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | PTGS1 2766/4885PTGS2 1124/4885CYP1A2 93/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | PTGS1 4439/4885PTGS2 4062/4885CYP1A2 3277/4885 |
| US-20110009351-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | CLINT1, SLC47A2, GOLT1B | PTGS1 4775/4885PTGS2 4802/4885CYP1A2 4717/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | PTGS1 204/4885PTGS2 239/4885CYP1A2 2305/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | PTGS1 204/4885PTGS2 239/4885CYP1A2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.